title: [Garlic effectiveness in rheumatoid arthritis].
abstract: OBJECTIVE
  To perform of clinical trial of alisate--a garlic preparation produced in Russia.
  
  
  METHODS
  An open controlled trial of alisate enrolled 30 patients with rheumatoid arthritis (RA). 15 patients with RA of varying clinical form, stage and activity were given alisate in a dose 300 mg (1 tablet) twice a day for 4-6 weeks. 15 control RA patients received conventional antirheumatic therapy.
  
  
  RESULTS
  The alisate group achieved a good and partial response in 86.5% of cases. The drug was well tolerated and had no side effects. In control group, some parameters changed for the worse.
  
  
  CONCLUSIONS
  Alisate can be recommended for treatment of RA patients in combined and monotherapy.
authors.forename: L N
authors.initials: LN
authors.lastname: Denisov
authors.forename: I V
authors.initials: IV
authors.lastname: Andrianova
authors.forename: S S
authors.initials: SS
authors.lastname: Timofeeva
mesh_terms: D000284:Administration, Oral; D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D005737:Garlic; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use; D010946:Plants, Medicinal; D012189:Retrospective Studies; D012217:Rheumatoid Factor / Q000097:blood; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D015415:Biomarkers; D010936:Plant Extracts; D002097:C-Reactive Protein; D012217:Rheumatoid Factor